Key Finding
This protocol will compare acupuncture and moxibustion combined with escitalopram versus medication alone or medication with rTMS for treating moderate acute depression in 300 participants.
This study is examining whether combining acupuncture and moxibustion with standard antidepressant medication can help people with moderate depression feel better faster and with fewer side effects. Researchers in China are enrolling 300 people with moderate depression in an open clinical trial. Participants will be divided into three groups: one receiving only escitalopram (a common antidepressant), one receiving escitalopram plus repetitive transcranial magnetic stimulation (rTMS, a brain stimulation therapy), and one receiving escitalopram plus integrated acupuncture and moxibustion treatments. The medication-only group will take their antidepressant as prescribed, while the combination groups will receive either rTMS five times weekly for three weeks or acupuncture and moxibustion three times weekly for six weeks. Researchers will measure depression symptoms using standard questionnaires, along with anxiety levels, sleep quality, treatment expectations, and safety markers like liver and kidney function. This is a protocol paper, meaning the study is just beginning and results are not yet available. The research aims to determine whether adding acupuncture and moxibustion to medication is safe, practical, and potentially more effective than medication alone for treating acute moderate depression. If successful, this approach could offer patients an additional treatment option that may work faster or reduce medication side effects. The findings could provide evidence supporting acupuncture as part of routine depression care in integrative medicine settings. If you're considering acupuncture for depression, consult with a licensed acupuncturist experienced in mental health treatment and coordinate care with your physician.
This single-center, open-label, pragmatic RCT will evaluate integrative acupuncture and moxibustion (iAM) as adjunctive therapy to escitalopram oxalate in 300 patients with moderate acute-phase depressive disorder. Participants will be randomized 1:1:1 to escitalopram alone, escitalopram plus rTMS (5x/week for 3 weeks), or escitalopram plus iAM (3x/week for 6 weeks). The primary outcome measure is the Hamilton Depression Rating Scale (HDRS). Secondary outcomes include Beck Depression Inventory-II, GAD-7, Hamilton Anxiety Scale, Insomnia Severity Index, Stanford Expectations of Treatment Scale, and hepatorenal function monitoring. This protocol addresses the clinical need for adjunctive therapies that may accelerate onset of action and improve adherence in antidepressant treatment. The pragmatic design reflects real-world clinical practice patterns where combined approaches are commonly employed. Results will provide evidence regarding feasibility, safety, and comparative effectiveness of iAM versus rTMS as augmentation strategies for moderate depression, informing integrative treatment protocols in mental health settings.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 Acupuncture combined with wet cupping therapy produced significantly greater improvements in depression scores and neurological function in post-stroke depression patients compared to acupuncture alone, accompanied by favorable changes in stress hormones and inflammatory markers.
📌 Menopausal women experience depression rates 2-3 times higher than premenopausal women due to estrogen fluctuations that disrupt neurotransmitter systems, HPA axis function, and trigger neuroinflammation.
📌 Nine percent of perinatal women experience persistent depression throughout pregnancy and postpartum, with distinct risk factors predicting different depressive symptom trajectories requiring individualized treatment approaches.